Top Industry Leaders in the Neuropathic Pain Market
*Disclaimer: List of key companies in no particular orderLatest Neuropathic pain Companies Update
October 2023: Anglo-French Drugs & Industries, located in India, introduced the AFD-NP as a novel medication for neuropathic pain. It is recommended to use this combination of Nortriptyline and Pregabalin to treat moderate to severe Neuropathic Pain. The Drug Control Department has approved this product. The two chemicals that make up AFD-NP are Nortriptyline 10 mg and Pregabalin 75 mg. Neuropathy patients struggle to fall asleep due to the excruciating pain and suffering they endure. Furthermore, the pain is chronic, which means that it persists for a long time. Nortriptyline has been demonstrated to greatly lessen neuropathic pain and to aid in extending sleep duration. It is quite helpful in cases of mild to severe neuropathy due to its feature. In addition, compared to gabapentin, pregabalin dramatically lowers the number of days with discomfort.
January 2023: Abbott, a global leader, announced that the FDA has given the go-ahead for their ProclaimTM XR spinal cord stimulation (SCS) system to treat severe diabetic peripheral neuropathy (DPN), a crippling consequence of diabetes. Patients with DPN in need of alternatives to conventional treatment modalities, such as oral medicine, may find relief with the Proclaim XR SCS system. Abbott's NeuroSphereTM Virtual Clinic, a linked care app that allows users to contact with a doctor and obtain treatment changes remotely, will be available to those who receive therapy from the Proclaim XR SCS system. Abbott is dedicated to developing life-changing solutions, including as diagnostics, nutritionals, medications, and medical devices like spinal cord stimulation, to help improve the lives of people with diabetes.
List of Neuropathic pain Key companies in the market
- Sanofi
- Abbott
- Astellas
- Pfizer
- Eli Lily
- Johnson and Johnson
- AstraZeneca
- GSK